Patents by Inventor Masakazu Miyazaki
Masakazu Miyazaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240166078Abstract: An information management system including a server. The server is configured to manage reservation information for reserving use of a charging device configured to charge a power storage device mounted on a battery electric vehicle. The server is configured to receive information for temporarily providing an authority for use of the battery electric vehicle to a renting person that rents the battery electric vehicle during a reservation time.Type: ApplicationFiled: September 18, 2023Publication date: May 23, 2024Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Hideki TAMOTO, Akinori MORISHIMA, Masami SUGANUMA, Taiki MIYAZAKI, Masakazu MOTOHASHI
-
Publication number: 20240157839Abstract: A server includes a storage storing data on chargers each configured to charge or discharge electric power to or from a vehicle with an electrical storage device, and a processor configured to send a user of the vehicle a message that makes a proposal to charge or discharge the vehicle by using at least one of the chargers when the vehicle travels toward a destination. The processor is configured to acquire, for each of the chargers, power supply and demand information on power demand or supply in a power grid of a region in which the charger is installed, extract a charger installed in a region with larger power demand or supply than another region from among the chargers based on predetermined information including the power supply and demand information, and send the message that makes a proposal to charge or discharge the vehicle by using the extracted charger.Type: ApplicationFiled: October 6, 2023Publication date: May 16, 2024Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Taiki Miyazaki, Masami Suganuma, Hideki Tamoto, Akinori Morishima, Masakazu Motohashi
-
Patent number: 11944620Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: April 2, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938131Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-(3-methoxy-4-4-(4-methylpiperazin-1-yl)piperidin-1-yl phenylamino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938132Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938133Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938130Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Publication number: 20230310422Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 5, 2023Publication date: October 5, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230301992Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 28, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277531Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277529Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277532Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277530Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230129146Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 21, 2022Publication date: April 27, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20220152020Abstract: Provided is a pharmaceutical composition containing 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof and a sweetener for reducing the bitterness of gilteritinib, suppressing the decrease in dissolution stability of gilteritinib due to, for example, stress such as heat and/or humidity over time, and having excellent dissolution stability. The pharmaceutical composition contains gilteritinib or a pharmaceutically acceptable salt thereof, a sweetener, and sugars and/or sugar alcohols.Type: ApplicationFiled: April 2, 2020Publication date: May 19, 2022Inventors: Akihiko SASAKI, Ko TANAKA, Masakazu MIYAZAKI, Seiji TAKAE
-
Publication number: 20200383977Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-4[-4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 24, 2020Publication date: December 10, 2020Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Patent number: 10786500Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 1, 2016Date of Patent: September 29, 2020Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Publication number: 20180185359Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 1, 2016Publication date: July 5, 2018Applicant: ASTELLAS PHARMA INC.Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Patent number: 9775832Abstract: Provided is a pharmaceutical composition for oral administration enabling improved solubility, improved dissolution properties, and improved oral absorbability of (2R)—N-({5-[3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazole-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropane imide amide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, as well as size reduction. The pharmaceutical composition for oral administration contains an amorphous form of compound A or its pharmaceutically acceptable salt, and a polymer.Type: GrantFiled: June 24, 2015Date of Patent: October 3, 2017Assignee: ASTELLAS PHARMA INC.Inventors: Hiroyuki Kojima, Masakazu Miyazaki, Mare Nishiura, Takashi Nishizato
-
Publication number: 20170143678Abstract: Provided is a pharmaceutical composition for oral administration enabling improved solubility, improved dissolution properties, and improved oral absorbability of (2R)—N-({5-[3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazole-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropane imide amide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, as well as size reduction. The pharmaceutical composition for oral administration contains an amorphous form of compound A or its pharmaceutically acceptable salt, and a polymer.Type: ApplicationFiled: June 24, 2015Publication date: May 25, 2017Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOJIMA, MASAKAZU MIYAZAKI, MARE NISHIURA, TAKASHI NISHIZATO